Complete Clinical Responders to Definite Chemoradiation in Esophageal Cancer : a Survival Analysis

Esophageal Cancer Clinical Trial

— CRCRT-EC  

Official title:

Predictors of Survival for Complete Clinical Responders to Definite Chemoradiation or Radiation Therapy for Esophageal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01525953
• Other study ID #: CRCRT-EC
• Status: Completed
• Phase: N/A
• First received: January 30, 2012
• Last updated: February 1, 2012
• Start date: January 2012
• Est. completion date: January 2012

Study information

• Verified date: February 2012
• Source: Centre Oscar Lambret
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: The Commission nationale de l’informatique et des libertés
• Study type: Observational

Clinical Trial Summary

The aim of this study is to identify prognostic factors for outcome in patients being complete clinical responders with chemoradiation or radiation for esophageal cancer

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: January 2012
• Est. primary completion date: January 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• localized or locally advanced esophageal cancer

• patient who underwent definite chemoradiation or radiation

• patient with complete clinical response

Exclusion Criteria:

• metastatic disease

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms

Intervention

Drug:
• Chemotherapy
Chemotherapy according to standard

Radiation:
• Radiotherapy
Radiotherapy according to local standard

Locations

Country	Name	City	State
France	Centre Oscar LAMBRET	Lille

Sponsors (1)

Lead Sponsor	Collaborator
Centre Oscar Lambret

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identification of prognostic factors for overall survival	Correlation between survival and baseline,clinical and treatment characteristics	From date of treatment until death, assessed up to 10 years	No
Secondary	Patterns of treatment failure	Type of recurrence : local, regional, distant.	From date of treatment until treatment failure, assessed up to 10 years	No
Secondary	Disease-free survival	Time between the end of treatment and the occurence of progression	From date of treatment until progression or death, assessed up to 10 years	No